CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

/UPDATE -- Seismic Pharmaceuticals/

Phase 3IstaroximePositive
AI Analysis

Summary

Seismic Pharmaceuticals has commenced a global Phase 3 trial of Istaroxime in patients with cardiogenic shock. The announcement represents advancement of the candidate into late-stage development.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.30
Phase 3 TrialCardiogenic ShockIstaroximeGlobal Trial
Related Companies

Read the original article

Published by PR Newswire Biotech on September 9, 2026 8:53 PM

Read Original